Contrast ultrasound perfusion imaging of lower extremities in peripheral arterial disease: a novel diagnostic method

Eur Heart J. 2006 Feb;27(3):310-5. doi: 10.1093/eurheartj/ehi636. Epub 2005 Nov 24.

Abstract

Aims: The purpose of this study was to establish contrast-enhanced ultrasound perfusion imaging (CUPI) of the lower extremities as a novel non-invasive diagnostic tool for patients with peripheral arterial disease (PAD).

Methods and results: Ultrasound contrast agent (SonoVue) was injected into a peripheral vein of 16 control subjects and 16 PAD patients and its appearance in the calf muscle was detected by low-energy harmonic ultrasound. Analysis of the wash-in curves revealed that PAD patients had a significantly longer time to peak intensity (TTP), i.e. duration of maximum contrast perfusion [37 s (19-79 s) in control subjects vs. 56 s (32-104 s) in PAD patients at rest, age-adjusted P=0.002]. Exercise stress test of the calf muscle resulted in a decrease of the TTP, maintaining the significant difference in TTP between the groups [19 s (8-37 s) in control subjects vs. 32 s (18-48 s) in PAD patients after exercise, age-adjusted P=0.004]. Neither ankle-brachial index and TTP nor age and TTP showed a significant correlation.

Conclusion: CUPI reflects the regional blood circulation of the calf muscle. In this pilot study, PAD patients show a significantly longer TTP than control subjects. The clinical relevance of CUPI is topic of ongoing studies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Contrast Media
  • Female
  • Humans
  • Intermittent Claudication / diagnostic imaging*
  • Intermittent Claudication / physiopathology
  • Leg / blood supply
  • Male
  • Middle Aged
  • Peripheral Vascular Diseases / diagnostic imaging*
  • Peripheral Vascular Diseases / physiopathology
  • Phospholipids*
  • Pilot Projects
  • Sulfur Hexafluoride*
  • Ultrasonography

Substances

  • Contrast Media
  • Phospholipids
  • contrast agent BR1
  • Sulfur Hexafluoride